指南与共识乳腺癌

ASCO 指南更新:HR 阳性/HER2 阴性转移性乳腺癌内分泌与靶向治疗

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2021-07-29

核心推荐包括:PIK3CA 突变患者可选用阿培利司联合内分泌治疗,BRCA1/2 突变携带者一线至三线可选用奥拉帕利或他拉唑帕利,以及 CDK4/6 抑制剂联合内分泌治疗的适用人群与时机。

要点

  • PIK3CA 突变者应接受阿培利司联合内分泌治疗,需用肿瘤组织或血浆 cfDNA 的 NGS 检测突变。
  • BRCA1/2 突变携带者一线至三线可选用奥拉帕利或他拉唑帕利。
  • 初治绝经后 HR 阳性 MBC 可用非甾体 AI 联合 CDK4/6 抑制剂。

核心结论

  • ASCO 更新了 HR 阳性/HER2 阴性转移性乳腺癌的系统治疗推荐,涵盖 PIK3CA 突变、BRCA1/2 突变及 CDK4/6 抑制剂使用等场景。

关键数值与推荐

  • 阿培利司联合内分泌治疗应提供给绝经后及男性 HR 阳性/HER2 阴性/PIK3CA 突变晚期或转移性乳腺癌患者,且既往内分泌治疗±CDK4/6 抑制剂。
  • 应使用肿瘤组织或血浆 cfDNA 的二代测序检测 PIK3CA 突变;cfDNA 未检出突变时,如有肿瘤组织应检测以发现少量额外 PIK3CA 突变患者。
  • 目前数据不足以推荐常规检测 ESR1 突变以指导 HR 阳性/HER2 阴性 MBC 治疗。
  • BRCA1/2 突变携带的转移性 HER2 阴性乳腺癌患者,一线至三线应提供奥拉帕利或他拉唑帕利。
  • 初治绝经后 HR 阳性 MBC 应提供非甾体 AI 联合 CDK4/6 抑制剂。

临床怎么用

  • 对 HR 阳性/HER2 阴性 MBC 患者,应基于 PIK3CA 和 BRCA1/2 突变状态选择阿培利司或 PARP 抑制剂。
  • 初治绝经后患者首选非甾体 AI 联合 CDK4/6 抑制剂;AI 进展且未用过 CDK4/6 抑制剂者可选氟维司群联合 CDK4/6 抑制剂。
  • 不常规检测 ESR1 突变指导治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS: Fifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations. RECOMMENDATIONS: Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, ABC, or MBC following prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. Clinicians should use next-generation sequencing in tumor tissue or cell-free DNA in plasma to detect PIK3CA mutations. If no mutation is found in cell-free DNA, testing in tumor tissue, if available, should be used as this will detect a small number of additional patients with PIK3CA mutations. There are insufficient data at present to recommend routine testing for ESR1 mutations to guide therapy for HR-positive, HER2-negative MBC. For BRCA1 or BRCA2 mutation carriers with metastatic HER2-negative breast cancer, olaparib or talazoparib should be offered in the 1st-line through 3rd-line setting. A nonsteroidal aromatase inhibitor (AI) and a CDK4/6 inhibitor should be offered to postmenopausal women with treatment-naïve HR-positive MBC. Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting.Additional information can be found at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021. PMID: 34324367. doi:10.1200/JCO.21.01392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。